BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 18336403)

  • 1. Second-line randomized trials in epithelial ovarian cancer.
    Vermorken JB
    Int J Gynecol Cancer; 2008; 18 Suppl 1():59-66. PubMed ID: 18336403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
    Lin H; Changchien CC
    Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized single-agents trials in recurrent epithelial ovarian cancer.
    Sessa C; Marsoni S
    Int J Gynecol Cancer; 2005; 15 Suppl 3():247-51. PubMed ID: 16343240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer.
    Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Blumenson LE
    Gynecol Oncol; 1998 Nov; 71(2):190-5. PubMed ID: 9826459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical application of oxaliplatin in epithelial ovarian cancer.
    Fu S; Kavanagh JJ; Hu W; Bast RC
    Int J Gynecol Cancer; 2006; 16(5):1717-32. PubMed ID: 17009963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
    Bookman MA
    Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
    Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment options in patients with recurrent ovarian cancer.
    Gadducci A; Conte P; Cianci C; Negri S; Genazzani AR
    Anticancer Res; 2001; 21(5):3557-64. PubMed ID: 11848523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
    Burger RA; Sill MW; Monk BJ; Greer BE; Sorosky JI
    J Clin Oncol; 2007 Nov; 25(33):5165-71. PubMed ID: 18024863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer.
    Douwes F; BogoviC J; Douwes O; Migeod F; Grote C
    Int J Clin Oncol; 2004 Apr; 9(2):85-91. PubMed ID: 15108039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?
    Markman M
    Gynecol Oncol; 2001 Apr; 81(1):1-2. PubMed ID: 11277641
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of platinum-resistant ovarian cancer.
    Trimble EL; Wright J; Christian MC
    Expert Opin Pharmacother; 2001 Aug; 2(8):1299-306. PubMed ID: 11584998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?
    Gronlund B; Høgdall C; Christensen IJ; Engelholm SA; Hansen HH
    Gynecol Oncol; 2004 Aug; 94(2):409-15. PubMed ID: 15297181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epithelial ovarian cancer].
    Hilpert F; Krause G; Venhoff L; Kühnle E; Schem C; Maass N
    Ther Umsch; 2007 Jul; 64(7):375-80. PubMed ID: 17948754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers.
    Goto T; Takano M; Ohishi R; Iwasa N; Shimizu M; Hasegawa K; Nagao S; Fujiwara K
    J Obstet Gynaecol Res; 2010 Aug; 36(4):764-8. PubMed ID: 20666942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug therapy for gynaecological cancer in older women.
    van Rijswijk RE; Vermorken JB
    Drugs Aging; 2000 Jul; 17(1):13-32. PubMed ID: 10933513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer.
    Le T; Hopkins L; Baines KA; Rambout L; Fung-Kee-Fung M
    Int J Gynecol Cancer; 2008; 18(3):428-31. PubMed ID: 17692088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.